Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global Phase 1/2 study for CB 4332 for CFI deficient patients

X
Trial Profile

A global Phase 1/2 study for CB 4332 for CFI deficient patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CB 4332 (Primary)
  • Indications Glomerulonephritis; Haemolytic uraemic syndrome; Immunodeficiency disorders; Membranoproliferative glomerulonephritis
  • Focus First in man; Therapeutic Use
  • Sponsors Catalyst Biosciences; Gyre Therapeutics
  • Most Recent Events

    • 09 Sep 2021 According to Catalyst Biosciences media release, the company anticipates the submission of an Investigational New Drug (IND) application and initiation of a global clinical trial for CB 4332 in CFI deficiency in 2022.
    • 08 Jul 2021 New trial record
    • 01 Jul 2021 According to Catalyst Biosciences media release, this trial is planned for 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top